{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:31:51Z","timestamp":1785407511723,"version":"3.56.0"},"posted":{"date-parts":[[2026,4,28]]},"group-title":"Neuroscience","reference-count":67,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000874","name":"Brain & Behavior Research Foundation","doi-asserted-by":"crossref","award":["NARSAD Young Investigator Award"],"award-info":[{"award-number":["NARSAD Young Investigator Award"]}],"id":[{"id":"10.13039\/100000874","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["DA054339"],"award-info":[{"award-number":["DA054339"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"award":["Innovation Award"],"award-info":[{"award-number":["Innovation Award"]}],"id":[{"id":"https:\/\/ror.org\/01e3m7079","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,4,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Antipsychotics are widely used chronically to treat several psychiatric conditions and off-label indications, but their clinical utility is often accompanied by motor and\/or metabolic side effects. Antipsychotics can also alter the brain\u2019s reward circuitry, and we recently showed that upon abrupt discontinuation, chronic treatment with the first-generation antipsychotic haloperidol increases cocaine relapse in a rodent model of i.v. cocaine self-administration. Here, we examined whether chronic treatment with second-generation antipsychotics was also associated with increased addiction vulnerability in rodents and humans, and sought to further characterize the cellular substrate linking antipsychotic exposure to substance use disorder (SUD).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Adult rats received subcutaneous infusion of risperidone, olanzapine, or vehicle for 14 days. Rats were then trained to self-administer i.v. cocaine or oral sucrose pellets for 10 days and active lever presses were paired with compound cue exposure. After a period of extinction training, reward seeking was reinstated by restoration of cues to active lever pressing for 20 minutes. To enable quantification of dendritic spine morphology and manipulation of MSNs during relapse, viral approaches were used to label D1- or D2-MSNs in the nucleus accumbens core (NAcore), a region that encodes reward-related responses and regulates symptoms associated with addiction and other psychiatric disorders, including schizophrenia. To assess the clinical relationship between chronic antipsychotic use and SUD, we conducted a systematic review and meta-analysis of studies identified through PubMed, CENTRAL, Scopus, and Embase that examined the effects of antipsychotic treatment on addictive substance use or craving in patients with SUD.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In rats, chronic risperidone or olanzapine treatment delayed extinction learning and increased cue-induced cocaine seeking, but did not alter seeking of the natural reward sucrose or its extinction. Cued relapse increased spine head diameter in NAcore D2-MSNs, but not D1-MSNs after antipsychotic treatment relative to vehicle-treated controls. Chemogenetic inhibition of D2-MSNs reversed addiction vulnerability conferred by antipsychotic treatment. In patients whose SUDs were treated with antipsychotics, duration of treatment (&gt;4 months) strongly predicted addictive substance use or craving independent of antipsychotic type (first- vs. second-generation) or misused substance (psychostimulant, opioid, alcohol, or cannabis).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Chronic antipsychotic treatment, regardless of drug class, was associated with increased vulnerability to addictive substance use and relapse-like behavior in a rat model, and was linked to potentiation of D2-MSNs in the ventral striatum. In humans, systematic review and meta-analytic findings supported this pattern in patients maintained on antipsychotic treatment.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.04.24.720671","type":"posted-content","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T05:10:28Z","timestamp":1777439428000},"source":"Crossref","is-referenced-by-count":0,"title":["Reward Circuit Adaptations After Chronic Antipsychotic Treatment Confer Addiction Vulnerability"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9267-9492","authenticated-orcid":false,"given":"Anna","family":"Kruyer","sequence":"first","affiliation":[{"name":"Division of Pharmaceutical Sciences, University of Cincinnati, Cincinnati, OH"},{"name":"Center for Addiction Research, University of Cincinnati, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariana","family":"Angelis","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor","family":"Waselenko","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Sciences, University of Cincinnati, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Tan","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Sciences, University of Cincinnati, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Xiong","sequence":"additional","affiliation":[{"name":"Division of Pharmacy Practice, University of Cincinnati, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3630-0147","authenticated-orcid":false,"given":"Davide","family":"Amato","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Sciences, University of Cincinnati, Cincinnati, OH"},{"name":"Center for Addiction Research, University of Cincinnati, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026043008001286000_2026.04.24.720671v1.1","doi-asserted-by":"crossref","unstructured":"Tesselaar DRM , Schellekens AFA , Homberg JR , Booij J , Guerrin C . Psychiatric comorbidity in substance use disorders, a systematic review of neuro-imaging findings. Neurosci Biobehav Rev. 2025;177:106325.","DOI":"10.1016\/j.neubiorev.2025.106325"},{"key":"2026043008001286000_2026.04.24.720671v1.2","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbp016"},{"issue":"3","key":"2026043008001286000_2026.04.24.720671v1.3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/jamapsychiatry.2013.3726","article-title":"Comorbidity of severe psychotic disorders with measures of substance use","volume":"71","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"2026043008001286000_2026.04.24.720671v1.4","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e3181a9163c"},{"key":"2026043008001286000_2026.04.24.720671v1.5","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0211"},{"key":"2026043008001286000_2026.04.24.720671v1.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2010.07.013"},{"key":"2026043008001286000_2026.04.24.720671v1.7","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2012.12010112"},{"key":"2026043008001286000_2026.04.24.720671v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2014.04.003"},{"key":"2026043008001286000_2026.04.24.720671v1.9","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-0992"},{"issue":"4","key":"2026043008001286000_2026.04.24.720671v1.10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jsat.2011.05.004","article-title":"A systematic review of interventions for co-occurring substance use disorder and borderline personality disorder","volume":"41","year":"2011","journal-title":"J Subst Abuse Treat"},{"key":"2026043008001286000_2026.04.24.720671v1.11","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.64.5.566"},{"key":"2026043008001286000_2026.04.24.720671v1.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2011.04.011"},{"key":"2026043008001286000_2026.04.24.720671v1.13","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.164.3.402"},{"key":"2026043008001286000_2026.04.24.720671v1.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(01)00261-4"},{"key":"2026043008001286000_2026.04.24.720671v1.15","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.2000.101006452.x"},{"key":"2026043008001286000_2026.04.24.720671v1.16","doi-asserted-by":"publisher","DOI":"10.1177\/0004867414525838"},{"issue":"4","key":"2026043008001286000_2026.04.24.720671v1.17","first-page":"306","article-title":"Comparing violence in schizophrenia patients with and without comorbid substance-use disorders to community controls","volume":"128","year":"2013","journal-title":"Acta Psychiatr Scand"},{"key":"2026043008001286000_2026.04.24.720671v1.18","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.84.2.265"},{"key":"2026043008001286000_2026.04.24.720671v1.19","doi-asserted-by":"publisher","DOI":"10.1017\/S003329170500574X"},{"key":"2026043008001286000_2026.04.24.720671v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2007.04.022"},{"key":"2026043008001286000_2026.04.24.720671v1.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2006.04.004"},{"key":"2026043008001286000_2026.04.24.720671v1.22","doi-asserted-by":"publisher","DOI":"10.1176\/ps.47.8.853"},{"key":"2026043008001286000_2026.04.24.720671v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.07.011"},{"key":"2026043008001286000_2026.04.24.720671v1.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2017.04.016"},{"key":"2026043008001286000_2026.04.24.720671v1.25","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.131.6.724-a"},{"key":"2026043008001286000_2026.04.24.720671v1.26","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.142.11.1259"},{"key":"2026043008001286000_2026.04.24.720671v1.27","doi-asserted-by":"publisher","DOI":"10.3109\/10673229709030550"},{"key":"2026043008001286000_2026.04.24.720671v1.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.avb.2012.11.014"},{"key":"2026043008001286000_2026.04.24.720671v1.29","doi-asserted-by":"publisher","DOI":"10.1007\/BF00426397"},{"key":"2026043008001286000_2026.04.24.720671v1.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01235-6"},{"key":"2026043008001286000_2026.04.24.720671v1.31","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0405-4"},{"key":"2026043008001286000_2026.04.24.720671v1.32","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-984463"},{"key":"2026043008001286000_2026.04.24.720671v1.33","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbs077"},{"key":"2026043008001286000_2026.04.24.720671v1.34","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145711000010"},{"key":"2026043008001286000_2026.04.24.720671v1.35","doi-asserted-by":"publisher","DOI":"10.1177\/2045125315583820"},{"key":"2026043008001286000_2026.04.24.720671v1.36","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.neubiorev.2017.09.027","article-title":"Dopamine, the antipsychotic molecule: A perspective on mechanisms underlying antipsychotic response variability","volume":"85","year":"2018","journal-title":"Neurosci Biobehav Rev"},{"key":"2026043008001286000_2026.04.24.720671v1.37","doi-asserted-by":"crossref","unstructured":"Amato D , Canneva F , Cumming P , Maschauer S , Groos D , Dahlmanns JK , et al. A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter. Mol Psychiatry. 2018.","DOI":"10.1038\/s41380-018-0114-5"},{"issue":"10241","key":"2026043008001286000_2026.04.24.720671v1.38","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(20)30233-6","article-title":"Antipsychotics for schizophrenia and substance misuse - Authors\u2019 reply","volume":"395","year":"2020","journal-title":"Lancet"},{"issue":"10241","key":"2026043008001286000_2026.04.24.720671v1.39","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/S0140-6736(20)30237-3","article-title":"Antipsychotics for schizophrenia and substance misuse","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"2026043008001286000_2026.04.24.720671v1.40","doi-asserted-by":"publisher","DOI":"10.3171\/2022.5.JNS212548"},{"key":"2026043008001286000_2026.04.24.720671v1.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2013.01.005"},{"key":"2026043008001286000_2026.04.24.720671v1.42","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0791-18.2018"},{"issue":"9","key":"2026043008001286000_2026.04.24.720671v1.43","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1089\/cap.2018.0037","article-title":"A Focused Review on the Treatment of Pediatric Patients with Atypical Antipsychotics","volume":"28","year":"2018","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2026043008001286000_2026.04.24.720671v1.44","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2012.647"},{"key":"2026043008001286000_2026.04.24.720671v1.45","doi-asserted-by":"crossref","unstructured":"Meza N , Franco JV , Sguassero Y , Nunez V , Escobar Liquitay CM , Rees R , et al. Atypical antipsychotics for autism spectrum disorder: a network meta-analysis. Cochrane Database Syst Rev. 2025;5(5):CD014965.","DOI":"10.1002\/14651858.CD014965.pub2"},{"issue":"1","key":"2026043008001286000_2026.04.24.720671v1.46","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.psc.2024.08.008","article-title":"Pharmacotherapy for Tourette Syndrome","volume":"48","year":"2025","journal-title":"Psychiatr Clin North Am"},{"key":"2026043008001286000_2026.04.24.720671v1.47","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2012.18.s5-b.1"},{"key":"2026043008001286000_2026.04.24.720671v1.48","doi-asserted-by":"publisher","DOI":"10.2174\/1381612821666150619092903"},{"key":"2026043008001286000_2026.04.24.720671v1.49","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20240738"},{"key":"2026043008001286000_2026.04.24.720671v1.50","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1999.9433273.x"},{"key":"2026043008001286000_2026.04.24.720671v1.51","doi-asserted-by":"crossref","unstructured":"Gass JT , Chandler LJ . The Plasticity of Extinction: Contribution of the Prefrontal Cortex in Treating Addiction through Inhibitory Learning. Front Psychiatry. 2013;4:46.","DOI":"10.3389\/fpsyt.2013.00046"},{"key":"2026043008001286000_2026.04.24.720671v1.52","doi-asserted-by":"publisher","DOI":"10.1101\/lm.1041309"},{"issue":"12","key":"2026043008001286000_2026.04.24.720671v1.53","doi-asserted-by":"crossref","first-page":"113488","DOI":"10.1016\/j.celrep.2023.113488","article-title":"Nucleus accumbens local circuit for cue-dependent aversive learning","volume":"42","year":"2023","journal-title":"Cell Rep"},{"key":"2026043008001286000_2026.04.24.720671v1.54","doi-asserted-by":"publisher","DOI":"10.1101\/lm.042507.116"},{"key":"2026043008001286000_2026.04.24.720671v1.55","doi-asserted-by":"crossref","unstructured":"Macpherson T , Kim JY , Hikida T . Nucleus Accumbens Core Dopamine D2 Receptor-Expressing Neurons Control Reversal Learning but Not Set-Shifting in Behavioral Flexibility in Male Mice. Front Neurosci. 2022;16:885380.","DOI":"10.3389\/fnins.2022.885380"},{"key":"2026043008001286000_2026.04.24.720671v1.56","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291721004591"},{"key":"2026043008001286000_2026.04.24.720671v1.57","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.046987"},{"key":"2026043008001286000_2026.04.24.720671v1.58","doi-asserted-by":"publisher","DOI":"10.1177\/070674370004500302"},{"issue":"6","key":"2026043008001286000_2026.04.24.720671v1.59","first-page":"624","article-title":"The Laboratory Rat: Relating Its Age With Human\u2019s","volume":"4","year":"2013","journal-title":"Int J Prev Med"},{"key":"2026043008001286000_2026.04.24.720671v1.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2005.04.002"},{"key":"2026043008001286000_2026.04.24.720671v1.61","doi-asserted-by":"crossref","unstructured":"Parrilla-Carrero J , Kruyer A , Chalhoub RM , Powell C , Resendez SL , Amato D . Neuronal signature of an antipsychotic response. Research Square. 2020.","DOI":"10.21203\/rs.3.rs-72975\/v1"},{"key":"2026043008001286000_2026.04.24.720671v1.62","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-008-1245-1"},{"issue":"6","key":"2026043008001286000_2026.04.24.720671v1.63","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1176\/appi.ps.201500482","article-title":"Off-Label Prescribing of Psychotropic Medication, 2005-2013: An Examination of Potential Influences","volume":"68","year":"2017","journal-title":"Psychiatr Serv"},{"key":"2026043008001286000_2026.04.24.720671v1.64","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2082"},{"key":"2026043008001286000_2026.04.24.720671v1.65","doi-asserted-by":"publisher","DOI":"10.1021\/cn3000923"},{"issue":"8","key":"2026043008001286000_2026.04.24.720671v1.66","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.biopsych.2024.03.014","article-title":"Muscarinic Receptor Activators as Novel Treatments for Schizophrenia","volume":"96","year":"2024","journal-title":"Biol Psychiatry"},{"issue":"18","key":"2026043008001286000_2026.04.24.720671v1.67","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1080\/14656566.2022.2145884","article-title":"Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia","volume":"23","year":"2022","journal-title":"Expert Opin Pharmacother"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.04.24.720671","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:00:35Z","timestamp":1777561235000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.04.24.720671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":67,"URL":"https:\/\/doi.org\/10.64898\/2026.04.24.720671","relation":{},"subject":[],"published":{"date-parts":[[2026,4,28]]},"subtype":"preprint"}}